Unique Targeting of the Gut for Metabolic Benefit
3:10 pm - Thursday 16th July 2026
- Leveraging bariatric bypass clinical insights with novel oral small-molecule pharmaceuticals
- Synergy with rapidly evolving metabolic armamentarium
- Well-tolerated and effective early treatment choice alongside metformin and SGLT2s while complementing incretin-based therapies
